Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma".
作者信息
Nishida Naoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):635-639. doi: 10.3350/cmh.2025.0071. Epub 2025 Jan 24.
Abstract
摘要
相似文献
1
Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma".
Clin Mol Hepatol. 2025 Apr;31(2):635-639. doi: 10.3350/cmh.2025.0071. Epub 2025 Jan 24.
2
Integrated molecular characterization of sarcomatoid hepatocellular carcinoma.
Clin Mol Hepatol. 2025 Apr;31(2):426-444. doi: 10.3350/cmh.2024.0686. Epub 2024 Dec 10.
3
Correspondence to editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma".
Clin Mol Hepatol. 2025 Apr;31(2):e192-e193. doi: 10.3350/cmh.2025.0183. Epub 2025 Feb 26.
4
Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts.
Mod Pathol. 2023 Jan;36(1):100042. doi: 10.1016/j.modpat.2022.100042.
5
Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
J Med Case Rep. 2022 May 18;16(1):193. doi: 10.1186/s13256-022-03426-3.
6
HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma.
Cancer Sci. 2017 Jul;108(7):1328-1337. doi: 10.1111/cas.13277. Epub 2017 Jun 14.
7
Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities.
Cancers (Basel). 2019 Dec 31;12(1):99. doi: 10.3390/cancers12010099.
8
Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome.
Cancer Med. 2021 Sep;10(18):6227-6238. doi: 10.1002/cam4.4162. Epub 2021 Jul 31.
9
Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.
Aging (Albany NY). 2021 Jun 3;13(11):15126-15138. doi: 10.18632/aging.203076.
10
Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors.
World J Oncol. 2020 Oct;11(5):183-187. doi: 10.14740/wjon1325. Epub 2020 Oct 15.
引用本文的文献
1
Correspondence to editorial on "Integrated molecular characterization of sarcomatoid hepatocellular carcinoma".
Clin Mol Hepatol. 2025 Apr;31(2):e192-e193. doi: 10.3350/cmh.2025.0183. Epub 2025 Feb 26.
本文引用的文献
1
Integrated molecular characterization of sarcomatoid hepatocellular carcinoma.
Clin Mol Hepatol. 2025 Apr;31(2):426-444. doi: 10.3350/cmh.2024.0686. Epub 2024 Dec 10.
2
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
Clin Mol Hepatol. 2025 Jan;31(1):311-315. doi: 10.3350/cmh.2024.0739. Epub 2024 Sep 3.
3
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity.
Cell. 2024 Jun 20;187(13):3390-3408.e19. doi: 10.1016/j.cell.2024.04.025. Epub 2024 May 15.
4
Impact of Mutations in Subunit Genes of the Mammalian SWI/SNF Complex on Immunological Tumor Microenvironment.
Cancer Genomics Proteomics. 2024 Jan-Feb;21(1):88-101. doi: 10.21873/cgp.20432.
5
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.
Lancet Gastroenterol Hepatol. 2023 Aug;8(8):760-770. doi: 10.1016/S2468-1253(23)00147-4. Epub 2023 Jun 14.
6
Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts.
Mod Pathol. 2023 Jan;36(1):100042. doi: 10.1016/j.modpat.2022.100042.
7
Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients.
Front Oncol. 2023 Jan 17;12:1086908. doi: 10.3389/fonc.2022.1086908. eCollection 2022.
8
A ruptured sarcomatoid hepatocellular carcinoma treated with combined immunotherapy.
Clin J Gastroenterol. 2023 Apr;16(2):244-249. doi: 10.1007/s12328-023-01758-1. Epub 2023 Jan 10.
9
Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221129470. doi: 10.1177/23247096221129470.
10
Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma.
Ann Transl Med. 2022 Apr;10(7):394. doi: 10.21037/atm-21-4322.
Zotero 插件